Axogen, Inc. (AXGN)
| Market Cap | 1.65B |
| Revenue (ttm) | 225.21M |
| Net Income (ttm) | -15.70M |
| Shares Out | 51.90M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | 67.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 898,612 |
| Open | 31.44 |
| Previous Close | 31.90 |
| Day's Range | 30.86 - 31.79 |
| 52-Week Range | 9.22 - 36.00 |
| Beta | 0.96 |
| Analysts | Strong Buy |
| Price Target | 36.11 (+13.8%) |
| Earnings Date | Feb 24, 2026 |
About AXGN
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstr... [Read more]
Financial Performance
In 2025, Axogen's revenue was $225.21 million, an increase of 20.21% compared to the previous year's $187.34 million. Losses were -$15.70 million, 57.6% more than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for AXGN stock is "Strong Buy." The 12-month stock price target is $36.11, which is an increase of 13.80% from the latest price.
News
Axogen Q4: EPS Miss Amid Biologics Transition
Axogen, Inc. (AXGN) reported strong 21% revenue growth but missed EPS expectations, prompting an 8% share decline and highlighting near-term margin pressures. AXGN is transitioning to a regulated biol...
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript
First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review
First Eagle Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of 1.71% in fourth quarter 2025. Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of ...
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Wasatch Micro Cap Fund Q4 2025 Performance Review
Leading individual contributors to the Fund's relative performance included Axogen, Inc., a holding within the health-care equipment industry. A provider of prepared food items such as meatballs and p...
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla.
Axogen Announces Proposed Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla.
Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of periph...
FDA approves Axogen's nerve repair graft
The U.S. Food and Drug Administration has approved Axogen's nerve repair graft, the health regulator said on Wednesday.
Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen
Axogen, Inc. delivered strong Q3 '25 results, with revenue up 23.7% and a return to profitability, fueling bullish momentum. Surgeon adoption is accelerating ahead of the December 5th FDA decision on ...
Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors
The strongest contributor to Wasatch Micro Cap Value Fund performance for the quarter was Bel Fuse, Inc. Axogen, Inc. (AXGN) was also a top contributor, providing surgical solutions for peripheral ner...
Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript
Axogen, Inc. ( AXGN) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Michael Dale - President, CEO & Director Lindsey Hartley - Chief Financial Officer Rick Ditto Jens Schroed...
Axogen, Inc. Reports Third Quarter 2025 Financial Results
Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million
Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN
LOS ANGELES--(BUSINESS WIRE)--Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN.
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $AXGN--AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm.
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
ALACHUA, Fla. and TAMPA, Fla.
Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined
Axogen is compounding business capital at increasing returns which was reflected in Q2 earnings. The stock remains in a down-trend with investors compressing multiples paid on capital invested into th...
Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript
Axogen, Inc. (NASDAQ:AXGN) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Jens Schroeder Kemp - Chief Marketing Officer Lindsey Hartley - Chief Financial Officer Mich...
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025
ALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...
Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript
Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript